Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastoma With Chromosomal 2p Gain and Anaplastic Lymphoma Kinase and Tropomyosin Receptor Kinase Activation
(2022) In JCO Precision Oncology 6.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/b6e12492-8bc2-4ea7-93d2-3155ace7dd78
- author
- publishing date
- 2022
- type
- Contribution to journal
- publication status
- published
- subject
- in
- JCO Precision Oncology
- volume
- 6
- article number
- e2100271
- publisher
- American Society of Clinical Oncology
- external identifiers
-
- scopus:85124177737
- ISSN
- 2473-4284
- DOI
- 10.1200/PO.21.00271
- language
- English
- LU publication?
- no
- id
- b6e12492-8bc2-4ea7-93d2-3155ace7dd78
- date added to LUP
- 2025-03-19 11:45:59
- date last changed
- 2025-04-30 14:06:19
@article{b6e12492-8bc2-4ea7-93d2-3155ace7dd78, author = {{Treis, Diana and Umapathy, Ganesh and Fransson, Susanne and Guan, Jikui and Mendoza-García, Patricia and Siaw, Joachim T. and Wessman, Sandra and Murkes, Lena Gordon and Stenman, Jakob J.E. and Djos, Anna and Elfman, Lotta H.M. and Johnsen, John Inge and Hallberg, Bengt and Palmer, Ruth H. and Martinsson, Tommy and Kogner, Per}}, issn = {{2473-4284}}, language = {{eng}}, publisher = {{American Society of Clinical Oncology}}, series = {{JCO Precision Oncology}}, title = {{Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastoma With Chromosomal 2p Gain and Anaplastic Lymphoma Kinase and Tropomyosin Receptor Kinase Activation}}, url = {{http://dx.doi.org/10.1200/PO.21.00271}}, doi = {{10.1200/PO.21.00271}}, volume = {{6}}, year = {{2022}}, }